Hybio Pharmaceutical Co., Ltd. (SHE:300199)
China flag China · Delayed Price · Currency is CNY
18.69
-0.01 (-0.05%)
Jul 25, 2025, 3:07 PM CST

Hybio Pharmaceutical Company Description

Hybio Pharmaceutical Co., Ltd. engages in the development, manufacture, and commercialization of therapeutic peptides API and peptide-based drugs in China and internationally.

It offers liraglutide, semaglutide, and exenatide for diabetes; terlipressin, desmopressin, and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix, and atosiban for obstetrics and gynecology; customized peptides; working standards for the peptide APIs and related impurities; peptide CRO; and CDMO services, which include peptide API synthesis and purification process development, finish dosage form development, reference standard preparation and qualification, impurity and product quality study and analysis, GMP system meeting EU and FDA standard, international and Chinese regulatory, and dossier support.

The company was founded in 1998 and is based in Wuhan, China.

Hybio Pharmaceutical Co., Ltd.
CountryChina
Founded1998
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees1,035
CEOYu Pinxiang

Contact Details

Address:
No. 9, Linkong West Street
Wuhan
China
Phone86 75 5265 88037
Websitehybio.com.cn

Stock Details

Ticker Symbol300199
ExchangeShenzhen Stock Exchange
Fiscal YearJanuary - December
Reporting CurrencyCNY
ISIN NumberCNE1000011T7
SIC Code2834

Key Executives

NamePosition
Yu PinxiangExecutive President and Director
Honghong TuVice President, Chief Financial Officer and Accounting Supervisor
Di YangVice President, Secretary and Director
Zhaohui ZengVice President
Min ZhangVice President
Heng QuanVice President of Human Resource and Administration Department
Yu LiuVice President of Marketing